Cargando…
Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease: patient selection and perspectives
The safety and efficacy of the use of collagenase Clostridium histolyticum (CCH) for the treatment of Peyronie’s disease has been confirmed over the past several years. However, identification of the ideal patient population for use of this treatment is not well established. Multiple studies have at...
Autores principales: | Kuhlmann, Paige K, DeLay, Kenneth J, Anaissie, James, Hellstrom, Wayne JG, Yafi, Faysal A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338950/ https://www.ncbi.nlm.nih.gov/pubmed/28280315 http://dx.doi.org/10.2147/PPA.S113507 |
Ejemplares similares
-
Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie’s disease
por: Nguyen, Hoang Minh Tue, et al.
Publicado: (2017) -
Role of collagenase clostridium histolyticum in Peyronie’s disease
por: Peak, Taylor C, et al.
Publicado: (2015) -
Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie’s disease
por: Diao, Linley, et al.
Publicado: (2017) -
Peyronie’s disease – outcomes of collagenase clostridium histolyticum injection: A systematic review
por: Mefford, Austin T., et al.
Publicado: (2021) -
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option
por: Gabrielson, Andrew T, et al.
Publicado: (2017)